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Abstract: Endothelin receptor antagonism has emerged as an important therapeutic approach 
in pulmonary arterial hypertension (PAH). Bench to bedside scientiﬁ  c research has shown that 
endothelin-1 (ET-1) is overexpressed in several forms of pulmonary vascular disease and may 
play an important pathogenetic role in the development and progression of PAH. Oral endo-
thelin receptor antagonists (ERAs) improved exercise capacity, functional status, pulmonary 
hemodymanics, and delayed the time to clinical worsening in several randomized placebo-
controlled trials. Two ERAs are currently approved by the US Food and Drug Administration: 
bosentan, a dual ERA for patients with class III and IV PAH, and ambrisentan, a selective ERA 
for patients with class II and III PAH. Sitaxsentan, another selective ERA, has been approved 
in Europe, Canada, and Australia. The objective of this review is to evaluate the available 
evidence describing the pharmacology, efﬁ  cacy, safety, and tolerability, and patient-focused 
perspectives regarding the different types of endothelin receptor antagonists. Ongoing and 
forthcoming randomized trials are also highlighted including the approach of combining this 
class of drugs with other drugs that target different cellular pathways believed to be etiologi-
cally important in PAH.
Keywords: ambrisentan, bosentan, endothelin receptor antagonists, pulmonary arterial hyper-
tension, sitaxsentan
Introduction to newer approaches to management 
of pulmonary arterial hypertension
Since the discovery of endothelin-1 (ET-1) in the late 1980s, scientiﬁ  c research has 
established that excess synthesis of ET-1 is an important factor in the pathogenesis of 
pulmonary arterial hypertension (PAH). This led to the development of a class of drugs 
called endothelin receptor antagonists (ERAs). On the basis of a series of randomized 
controlled clinical trials, bosentan, ambrisentan, and sitaxsentan are licensed in the 
United States and/or Europe as monotherapy for patients with PAH in Group 1 World 
Health Organization (WHO) classiﬁ  cation (Table 1).
ET-1 is a potent vasoconstrictor that is overexpressed in the plasma and the lungs of 
patients with PAH, especially in the remodeled precapillary pulmonary microvasculature 
which is the site of increased pulmonary vascular resistance in PAH (Giaid et al 1993). 
Studies suggest that dysregulated proliferation and abnormal apoptosis of endothelial 
cells are integral to the development of PAH (Voelkel et al 1998; Humbert et al 2004; 
Michelakis 2006). Indeed, scientiﬁ  c work shows that excess ET-1 levels not only cause 
signiﬁ  cant vasoconstriction, but also result in both the abnormal growth pattern of endo-
thelial cells, smooth muscle cells, ﬁ  broblasts, and pericytes and inhibit apoptosis of both 
smooth muscle cells and endothelial cells (Jankov et al 2006; Shichiri et al 1997). These 
events may contribute to the ongoing vascular remodeling seen in PAH.Vascular Health and Risk Management 2008:4(5) 944
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Review of pharmacology, mode 
of action, pharmacokinetics 
of endothelin receptor antagonists 
with speciﬁ  c reference to differential 
effects of the various agents
Mode of action
ET-1 acts on two G protein-coupled receptors termed ETA and 
ETB (Arai et al 1990; Sakurai et al 1990). ETA receptors are 
abundant on smooth muscle, pericytes, and ﬁ  broblasts and their 
activation by ET-1 results in vasoconstriction and prolifera-
tion in vitro (Evans et al 1999). ETB receptors are present on 
endothelial cells as well as pulmonary artery smooth muscle 
cells. Distal lung microvasculature have a greater proportion 
of ETB receptors and the receptor density in distal arteries is 
twofold greater in pulmonary hypertensive patients compared 
to normal human pulmonary arteries (Davie et al 2002a). ET-1 
activates ETB receptors at low doses, whilst at higher doses ETA 
receptors are activated. Both ET-1 receptors mediate smooth 
muscle cell contraction (McCulloch et al 1996) and prolif-
eration (Davie et al 2002b). In addition, stimulation of ETB 
receptors results in the release of vasodilators and antiprolifera-
tive molecules such as prostacyclin and nitric oxide from the 
endothelium (de Nucci et al 1988), and results in ET-1 clear-
ance from circulation (Dupuis et al 1996a, b). Further animal 
work has shown that by blocking ETB receptors, ET-1 vaso-
constrictive activity is enhanced (via the ETA receptor), due 
to inhibition of the transient ETB induced vasodilatation and 
ET-1 clearance. In other animal models of  PAH, ETA receptor 
blockade decreased the degree of pulmonary hypertension by 
25% with no effect from the ETB receptor blockade (Black et al 
2003). Conversely, other studies showed that combined ETA 
and ETB receptor blockade inhibited ET-1 induced vasocon-
striction more effectively than the ETA blocker alone (Sato et al 
1995) and in monocrotaline-induced pulmonary hypertension, 
dual ETA/B blockade produced better survival than selective 
ETA blockade (Jasmin et al 2001). Nevertheless, selectively 
blocking the ETA receptors and preserving the vasodilatory 
and clearance function of the ETB receptors may be of ben-
eﬁ  t in patients where excess synthesis of ET-1 rather than 
reduced clearance is resulting in excess pulmonary vascular 
constriction (Langleben et al 2006). However, because there 
are differences between experimental and clinical forms of 
PAH and clinical studies have not been performed to address 
if there are clinically signiﬁ  cant differences between dual and 
selective ERAs, the therapeutic superiority of selective versus 
combined ET receptor blockade remains unanswered and has 
been subject to great debate.
Two ERAs are on the US market: bosentan (Tracleer®, 
Actelion Pharmaceuticals Ltd, Allschwil, Switzerland) and 
ambrisentan (Letairis®, Gilead Sciences, Foster City, CA, 
USA). Sitaxsentan (Thelin®, Encysive Pharmaceuticals, 
Houston, Texas, USA) is approved in Canada, Europe, and 
Australia. Bosentan inhibits both the ETA and ETB recep-
tors (ETA: ETB 20:1) while ambrisentan (ETA: ETB 260:1) 
and sitaxsentan (ETA: ETB 6500:1) are selective for the ETA 
receptor (Battistini et al 2006).
Pharmacokinetics
Bosentan is dosed as 62.5 mg twice a day the ﬁ  rst 4 weeks 
and 125 mg twice a day thereafter (Dingemanse et al 2002a), 
ambrisentan is dosed 5 or 10 mg once a day (Galie et al 2005; 
Prod Info Letairis® oral tablets 2007), and sitaxsentan is 
dosed 100 mg once a day (Barst et al 2006). Unlike bosentan 
and sitaxsentan, ambrisentan has a propanoic acid structure 
(Battistini et al 2006). This difference may account for the 
lack of liver toxicity and/or lack of dug-drug interaction 
reported with ambrisentan.
Drug concentration levels
Bosentan administered orally reaches peak concentration 
within 3 to 5 hours and steady state by 3–5 days (Dingemanse 
et al 2002a). Concomitant administration of bosentan and 
inhibitors of CYP3A4 can increase the peak plasma concen-
tration by more than 2-fold (van Giersbergen et al 2002a). 
Oral ambrisentan reaches peak concentration within 2 hours 
Table 1 Pulmonary hypertension, Group I World Health 
Organization Classiﬁ  cation (after Venice 2003)
Group Ia
Idiopathic IPAH (IPAH)
Familial PAH (FPAH)
Related to
  •  Connective tissue diseases
  • HIV
  • Portal  hypertensionb
  • Anorexigens
  •  Congenital heart diseases
Primary pulmonary hypertension of the newborn (PPHN)
PAH with venule/capillary involvement (pulmonary veno-occlusive 
disease, PVOD) 
Others: Glycogen storage disease, Gaucher’s, hemoglobinopathies
(ie, sickle cell), hereditary hemorrhagic telagiectasia (HHT)
aEndothelin receptor anagonists have not been studied formally in portal hypertension, 
PPHN, PVOD and other types of group I PAH.
bGiven the potential for liver toxicity, caution is advised when using these agents in 
patients with portal hypertension due to end stage liver disease.Vascular Health and Risk Management 2008:4(5) 945
Endothelin receptor antagonists in pulmonary arterial hypertension
after administration (Prod Info Letairis® oral tablets 2007) 
and oral sitaxsentan reaches peak concentration within 1 to 
3 hours (Wu et al 2004b).
Absorption
Bosentan’s bioavailability is thought to be 50% and is similar 
for 125 mg tablet or with two 62.5 mg tablets (Dingemanse et al 
2002b). Ambrisentan is rapidly absorbed after oral administra-
tion but the bioavailability is unknown. Food has no effect on 
the bioavailability of ambrisentan or bosentan. Sitaxsentan’s 
oral bioavailability is greater than 90% (Widlitz et al 2005).
Distribution
All three ERAs are highly bound to plasma proteins (Wu 
et al 2004b; Dingemanse et al 2002a; Prod Info Letairis® 
oral tablets 2007).
Metabolism
Bosentan is extensively metabolized by the liver (Weber et al 
1996b). Ambrisentan is a strong inhibitor of P-glycoprotein, 
organic anion transport protein, cytochrome P450 and uri-
dine 5 diphosphate glucuronosyltransferases UGTs (Prod 
Info Letairis® oral tablets 2007). Sitaxsentan is a moderate 
inhibitor of liver cytochrome CYP2C9 (Widlitz et al 2005). 
It displays nonlinear metabolism at a dose of 300 mg, while 
100 mg dose has linear metabolism (Barst et al 2004).
Drug-drug interaction
All three drugs are contraindicated in conjunction with cyclo-
sporine A and glyburide (van Giersbergen et al 2002b; Treiber 
et al 2007). Bosentan induces warfarin metabolism and requires 
an increase in the warfarin dose (Murphey and Hood 2003), 
while sitaxsentan decreases warfarin metabolism, requiring a 
drop in the warfarin dose (Barst et al 2006). There are no known 
interactions between ambrisentan and warfarin.
Excretion
The elimination of bosentan is primarily through the biliary 
system with only 3% or less excreted through the kidneys 
(Weber et al 1996a). The elimination of ambrisentan is 
mainly by nonrenal pathways and the relative contributions 
of metabolism and biliary elimination have not been char-
acterized (Prod Info Letairis® oral tablets 2007). Fifty to 
60% of sitaxsentan is eliminated via the urine while the rest 
is eliminated via the feces (Wu et al 2004b).
Elimination half-life
The half-life of bosentan is 5–8 hours (Weber et al 1996a). 
The half-life of ambrisentan is 9–15 hours (Prod Info 
Letairis® oral tablets 2007). The half-life of sitaxsentan is 
6–7 hours (Wu et al 2004a).
Studies of the various endothelin 
antagonists in PAH
Table 2 summarizes the studies discussed in this review.
Bosentan
A pilot study of 7 patients with PAH showed that an infusion 
of high doses of bosentan acutely lowered both pulmonary 
and systemic vascular resistances (Williamson et al 2000). 
Several of the patients died or suffered clinical deterioration 
during the second phase of the study, which may have been 
related to their poor clinical status. ET-1 levels were elevated, 
consistent with a concomitant blockade of the endothelial 
ETB receptor.
These data led to the ﬁ  rst randomized, double-blind, 
placebo-controlled 12 week trial to evaluate the clinical 
effects of bosentan as a long-term oral treatment (Channick 
et al 2001). Oral bosentan (62.5 mg twice a day for 4 weeks, 
then 125 mg twice daily) improved exercise capacity 
(measured by 6-minute walk distance), pulmonary vascu-
lar resistance, and WHO functional class in patients with 
idiopathic PAH or PAH related to scleroderma. All patients 
had WHO functional class III at baseline. In both groups, 
more patients had idiopathic PAH than PAH related to 
scleroderma. The main difference between the groups was 
the slightly longer duration of disease before the diagnosis in 
patients assigned placebo than those assigned bosentan. The 
incidence of hepatotoxicity in bosentan treated patients was 
10% and resolved with discontinuation of the drug.
A 16 week, double blind, placebo-controlled study, 
the Bosentan Randomized Trial of Endothelin Antagonist 
Therapy (BREATHE-1) showed that patients treated with 
oral bosentan (62.5 mg twice a day for 4 weeks, then either 
125 mg or 250 mg twice daily) had improved exercise capacity 
as measured by the 6-minute walk distance, and functional 
class, and it delayed time to clinical worsening compared with 
placebo (Rubin et al 2002). Most patients were in functional 
class III, with a few in class IV. In both groups, more patients 
had idiopathic PAH than PAH associated with connective 
tissue disorders. Subgroup analysis suggested that bosentan 
improves the walking distance from baseline in patients with 
idiopathic PAH (46 m increase as opposed to a 5 m decline 
in the placebo group) while bosentan appeared to prevent 
deterioration in the walking distance only among patients 
with scleroderma. Abnormal hepatic function was found to 
be dose dependent. Increases in hepatic transaminase levels to Vascular Health and Risk Management 2008:4(5) 946
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more than 8 times the upper limit of normal was seen only in 
the bosentan groups; 3% in the group receiving 125 mg twice 
daily and 7% in the group receiving 250 mg twice daily, with 
the two doses exhibiting similar efﬁ  cacy on the end points. 
A substudy subsequently showed that bosentan improved right 
ventricular size and systolic function as well as left ventricu-
lar ﬁ  lling according to echocardiography (Galie et al 2003). 
BREATHE-1 resulted in approval of the ﬁ  rst oral therapy 
for PAH. The recommended dose for bosentan in adults is 
62.5 mg twice daily for 4 weeks and then increase to 125 mg 
twice daily long-term so long as there is no hepatotoxicity.
A 1-year follow-up open label study to determine the 
long-term beneﬁ  t of bosentan and in particular whether toler-
ance develops over time was assessed in patients with class III 
functional status at baseline (Sitbon et al 2003). Six-minute 
walk distances, pulmonary hemodynamics, and functional 
status were sustained for many patients. By 1 year, only 55% 
of patients were still in class III, while 40% had improved 
to class II. Only 4 of 29 patients required up-titration to 
250 mg twice daily to maintain a favorable clinical status. 
The incidence of hepatotoxicity was 9.7%, but was not severe 
enough to warrant discontinuation of the drug.
Two-year survival rates for bosentan in 2 observational 
cohorts (McLaughlin et al 2005; Sitbon et al 2005) were 
similar (89% and 91% respectively) and they are better 
than the predicted survival rate of 57% based on the equa-
tion formulated by the NIH registry. Factors that predicted 
a worse outcome included WHO functional class IV and 
6-minute walk distance below the median (358 m) at baseline 
(McLaughlin et al 2005). However, the lack of a control 
group and the comparison with a historical group, which 
probably had more severe patients, may bias the results 
toward bosentan therapy and limit our ability to determine 
that bosentan improves survival.
Five additional studies evaluated the efﬁ  cacy of bosen-
tan for patients with pulmonary hypertension associated 
with other diseases and age groups. BREATHE-3 showed 
improved pulmonary hemodynamics in 19 pediatric patients 
with PAH related to congenital heart disease after a 12-week 
open-label weight adjusted bosentan therapy trial (Barst et al 
2003). Approximately 50% of the patients were on concomi-
tant epoprostenol therapy. In BREATHE-4, patients with 
HIV-related PAH showed improved 6-minute walk distance, 
functional class, hemodynamics, Doppler echocardiographic 
indices, and quality of life in a 16 week open label study of 
bosentan therapy (Sitbon et al 2004). There was a 9% incidence 
of hepatotoxcity and there were no adverse interactions related 
to antiretroviral medications. BREATHE-5 evaluated bosentan Vascular Health and Risk Management 2008:4(5) 948
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therapy in 54 patients with class III PAH due to congenital 
heart disease and Eisenmenger’s syndrome in a randomized 
double blinded placebo controlled study over 16 weeks (Galie 
et al 2006). Bosentan therapy improved hemodynamics and 
exercise capacity in these patients.
Bosentan has also shown to improve functional capacity 
and symptoms in two prospective studies enrolling patients 
with pulmonary hypertension secondary to inoperable 
thromboembolic disease (Bonderman et al 2005; Hoeper 
et al 2005).
Ambrisentan
Ambrisentan is an endothelin receptor antagonist that 
is selective for ETA with a bioavailability and half-life 
(9–15 hours) that allows once a day dosing. A 12-week 
blinded to dose but without a placebo armed study was 
performed to determine the efﬁ  cacy and safety of 4 doses 
in patients with PAH (Galie et al 2005). Patients at all doses 
(1, 2.5, 5, or 10 mg daily) had improved 6-minute walk 
distance, functional class, Borg scale, and hemodynamics 
as compared with baseline. Adverse events were mild and 
unrelated to dose, including the 3% incidence of elevated 
hepatic transaminases of 3x the upper limit of normal. 
Subgroup analysis showed that patients with idiopathic 
PAH appeared to have a dose-response relationship for the 
6-minute walk distance.
In a phase III, randomized, double-blinded, placebo-
controlled, multicenter, efﬁ  cacy study of ambrisentan in 
subjects with PAH (ARIES-1), 202 patients were randomly 
assigned to 5 mg or 10 mg of ambrisentan or placebo once 
daily. There were signiﬁ  cant improvements in 6-minute walk 
distance, functional class, Borg dyspnea score, and quality 
life score (Oudiz et al 2006). In ARIES-2, patients with PAH 
were randomly assigned to placebo, ambrisentan 2.5 mg, or 
ambrisentan 5 mg once daily over 12 weeks (Olschewski 
et al 2006). There were also signiﬁ  cant improvements in 
6-minute walk distance and a delay to clinical worsening. No 
signiﬁ  cant adverse events occurred including no interaction 
with warfarin therapy, nor did any patient develop elevated 
hepatic transaminases above 3x the upper limit of normal.
Sitaxsentan
Sitaxsentan was evaluated in an open-label pilot study to 
determine the safety and efﬁ  cacy of 12 weeks of therapy on 
exercise capacity and hemodynamics in children and adults 
with idiopathic PAH, and associated diseases of  PAH such as 
congenital heart disease and collagen vascular disease (Barst 
et al 2002). The study demonstrated signiﬁ  cant increases 
in 6-minute walk distances and improved hemodynamics 
in patients who had functional class II, III, and IV PAH at 
doses between 100 to 500 mg twice daily. In the extension 
phase, 2 patients had severe hepatitis resulting in 1 death 
despite stopping the drug. The hepatic toxicity is related to 
the non-linear pharmacokinetics of sitaxsentan at high doses 
and thus subsequent studies have used doses up to 300 mg 
once a day.
This lead to STRIDE-1, the ﬁ  rst randomized double-
blinded placebo-controlled trial using lower doses of Sitax-
sentan (100 mg and 300 mg) and administering it only once 
daily for 12 weeks. STRIDE-1 included patients with idio-
pathic PAH and associated PAH diseases such as congenital 
heart disease and connective tissue disease and had no ceiling 
on the 6-minute walk distance, allowing patients with less 
severe PAH to be enrolled. STRIDE-1’s primary endpoint 
was peak oxygen consumption on the cardiopulmonary 
exercise testing and the results showed only an improvement 
in the percent of predicted peak oxygen consumption in the 
300 mg group compared with placebo. This index was sub-
sequently found to have interhospital variability, and thus its 
use in multi-center trials is questionable (Oudiz et al 2006). 
However, the secondary endpoints 6-minute walk distance, 
WHO functional class, and pulmonary hemodynamics all 
improved signiﬁ  cantly at both 100 mg and 300 mg doses. 
The most frequently reported clinical adverse events with 
sitaxsentan treatment were headache, peripheral edema, 
nausea, nasal congestion, and dizziness. The most frequently 
reported laboratory adverse event was increased international 
normalized ratio or prothrombin time, related to the effect 
of sitaxsentan on inhibition of CYP2C9 P450 enzyme, the 
principal enzyme involved in the metabolism of warfarin 
(Barst et al 2002). The incidence of elevated hepatic trans-
aminases above three times the upper limit of normal was 
0% at 100 mg dose and 10% at the 300 mg dose. However, 
by 26 weeks in the extension study (STRIDE-1X) there was 
a 5% incidence of elevated transaminases with the 100 mg 
dose and 21% incidence with the 300 mg dose.
A post-hoc subgroup analysis was performed on 42 
patients who had PAH associated with connective tissue 
disease out of the 178 patients enrolled in STRIDE-1 (Girgis 
et al 2007). Those patients treated with 100 mg or 300 mg of 
sitaxsentan had signiﬁ  cant improvements in their 6-minute 
walk distance (a mean of 58 m placebo-subtracted treat-
ment effect, p = 0.027), quality of life, and hemodynamics. 
Sitaxsentan appears to be tolerated well with only two 
patients that developed elevation of hepatic transaminases. 
A 1-year follow-up STRIDE-1 study, revealed that eleven Vascular Health and Risk Management 2008:4(5) 949
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PAH patients tolerated 100 mg of sitaxsentan daily well 
with sustained improvement in functional class, pulmo-
nary vascular resistance, and cardiac output (Langleben 
et al 2004).
An 18-week, double-blinded study compared sitaxsen-
tan at 50 mg or 100 mg to placebo or open label bosentan 
(62.5 mg twice daily for 4 weeks and then 125 mg twice 
daily) (STRIDE-2) (Barst et al 2006). The 100 mg sitaxsentan 
and the bosentan arms, but not the 50 mg sitaxsentan arm, 
showed signiﬁ  cant and similar improvements in 6-minute 
walk distance and functional class. The incidence of elevated 
hepatic transaminases (3x the upper limit of normal) was 
3% for 100 mg sitaxsentan, 5% for 50 mg sitaxsentan, 11% 
for bosentan, and 6% for placebo. STRIDE-4 is another 
study comparing 50 mg with 100 mg dose of sitaxsentan and 
placebo in Latin America, Poland, and Spain, which enrolled 
mostly patients in NYHA functional class II (Pulido et al 
2006). The 100 mg dose improved 6-minute walk distance, 
functional class, Borg dyspnea scale, and time to clinical 
worsening, while the 50 mg dose did not. Interestingly, how-
ever, the placebo groups also had a signiﬁ  cant improvement 
in 6-minute walk distance by 34 m. This placebo improve-
ment effect is thought to be due to the perception of improved 
medical care after enrollment among patients who might not 
otherwise have had access to that level of care. Patients toler-
ated sitaxsentan well with only 1 patient in each group devel-
oping elevated hepatic transaminases. In the STRIDE-2X 
extension open-label study (Benza et al 2006), patients who 
initially received 50 mg of sitaxsentan were given 100 mg and 
those who were on placebo were either assigned to 100 mg 
of sitaxsentan daily or 125 mg twice daily of bosentan, while 
those patients on either 100 mg of sitaxsentan or 125 mg of 
bosentan remained on the same therapy. At one year time to 
clinical worsening and liver function test abnormalities were 
better in the sitaxsentan group. In addition, the 1-year risk of 
discontinuation from monotherapy was 25% for sitaxsentan 
versus 42% for bosentan (p = 0.003). However, these inter-
pretations should be made with caution, as the study was not 
powered to detect differences between treatments. STRIDE-3 
is a long-term safety trial with over 800 patients enrolled and 
the results have not been reported yet.
STRIDE-6 (Benza et al 2007) studied the safety and efﬁ  -
cacy of sitaxsentan in patients discontinuing bosentan due to 
hepatotoxicity or inadequate efﬁ  cacy. After 12 weeks, only 
1 of the 12 patients who had previously experienced hepato-
toxicity on bosentan developed elevated liver enzymes with 
sitaxsentan. Five of  the 15 (33%) who discontinued bosentan 
because of lack of efﬁ  ciency had an improvement in 6-minute 
walk distance of more than 115% while taking sitaxsentan. 
No long-term data are yet available for this group.
Combination therapy with 
endothelin receptor antagonists
Patients’ quality of life and survival with PAH still remain 
poor despite the tremendous medical advances with mono-
therapy. This has led to attempts to combine different classes 
of therapies that have different actions such as ERAs with 
phosphodiesterase-5 inhibitors (eg, sildenafil) or pros-
tanoids (eg, epoprostonol, trepostinil, iloprost, or beraprost). 
Unfortunately, studies to ascertain what combinations are 
beneﬁ  cial and which have potential for adverse drug-drug 
interactions have not been conducted. A pilot pharmacologic 
study assessed the combination of bosentan with sildenaﬁ  l 
(a phosphodiesterase-5 inhibitor approved for the treatment 
of  PAH) in 10 patients with PAH (Paul et al 2005). Bosentan 
was given 62.5 mg twice daily for 1 month, then 125 mg 
twice daily for a second month. Sildenaﬁ  l 100 mg was given 
before the ﬁ  rst bosentan dose and at the end of each month 
of bosentan treatment. Treatment with bosentan 62.5 mg 
twice daily was associated with a 2-fold increase in sildenaﬁ  l 
clearance. Increasing the dose of bosentan to 125 mg twice 
daily led to a further increase in sildenaﬁ  l oral clearance, 
demonstrating that bosentan decreases the plasma concentra-
tion of sildenaﬁ  l. Preliminary results from the EARLY trial 
(Rubin et al 2007) looking at 29 patients with mild PAH 
(WHO functional class II) on sildenaﬁ  l in whom bosentan 
was added showed that the addition of bosentan decreased 
pulmonary vascular resistance by 20% and a delay to clini-
cal worsening, although there was no improvement in the 
6-minute walk distance. A recent study evaluated whether 
combination therapy after failure of bosentan monotherapy, 
particularly in patients with scleroderma-associated PAH 
(PAH-SSD) was effective. Addition of sildenaﬁ  l improved 
New York Heart Association class and 6-min walk distance in 
idiopathic PAH patients but failed to improve either param-
eter in PAH-SSD patients (Mathai et al 2007). Another study 
evaluated the addition of bosentan in PAH patients already 
on either inhaled iloprost or oral beraprost, two prostanoids. 
The addition of bosentan in an open-label fashion resulted in 
improved 6-minute walk distances after 3 months of com-
bined therapy and the therapy was well tolerated (Hoeper et al 
2003). In a 16-week BREATHE-2 study, patients already 
receiving intravenous epoprostenol had either bosentan or 
placebo added (Humbert et al 2004). The results were not 
as promising. Hemodynamics improved but not signiﬁ  -
cantly and there was no improvement in functional class or Vascular Health and Risk Management 2008:4(5) 950
Steiner and Preston
exercise capacity. This study, however, was not powered 
to detect differences in efﬁ  cacy. More importantly, there 
were serious adverse events, including death in the group 
receiving epoprostenol and bosentan. In the recent (STEP) 
combination trial, inhaled iloprost or placebo was added to 
patients receiving bosentan therapy (McLaughlin et al 2006). 
By week 12, patients receiving bosentan and iloprost had 
improved their New York Heart Association status by one 
class and had a delay to clinical worsening compared with 
those patients who were on bosentan and placebo. Also of 
note is that the post-inhalation iloprost-bosentan group had 
improved their pulmonary hemodynamics. A safety and 
efﬁ  cacy study (Hoeper et al 2006) of inhaled iloprost in 
those patients already treated with bosentan was terminated 
early after a futility analysis revealed that the primary end-
point, change in 6-minute walking distance, failed to show 
a positive effect of adding inhaled iloprost. Further studies 
involving larger sample sizes and long-term follow-up are 
needed to determine the efﬁ  cacy of adding inhaled iloprost 
to bosentan in patients with idiopathic PAH.
Transitioning from other 
PAH therapies to endothelin 
receptor antagonists
Transitioning patients onto oral therapy from parental 
forms of therapy is an attractive goal for our patients 
with PAH. The ﬁ  rst study reported 4 patients with normal 
hemodynamics on epoprostenol who were successfully 
transitioned to oral bosentan (Kim et al 2003). A sub-
sequent study evaluated three children who had normal 
hemodynamics on epoprostenol and showed that these 
children after having been switched to bosentan remained 
stable for a full 1-year study period (Ivy et al 2004). 
However, in subsequent studies that evaluated patients on 
parental prostanoids that did not normalize their pulmo-
nary hemodynamics prior to adding bosentan, only 75% 
transitioned successfully to bosentan and of those that 
transitioned more than 60% on bosentan therapy alone 
deteriorated within 3–16 months after the prostanoids were 
stopped (Suleman and Frost 2004; Steiner et al 2006). 
Given the high percentage of patients who deteriorate after 
they are transitioned to oral ERA therapy and the lack of 
randomized multicenter controlled trials evaluating the 
safety and efﬁ  cacy of transitioning patients, we recom-
mend only transitioning patients from prostaglandins to 
bosentan in those who have normalized their pulmonary 
hemodynamics and are under close observation.
Differential safety and tolerability
Both bosentan and sitaxsentan have been reported to cause 
hepatic toxicity, while ambrisentan seems to have no effects 
on the liver. In a post-market analysis of 4,994 patients on 
bosentan followed up prospectively for 30 months, the inci-
dence of liver function test elevation above 3 times the upper 
limit of normal was 7.6%, with an annual rate of 10.1% and 
a discontinuation rate of 3.7% (Humbert et al 2007). From 
the STRIDE trials, the incidence of liver abnormalities with 
sitaxsentan is approximately 5% with the 100 mg daily, 
while ambrisentan does not seem to affect liver function. 
Nevertheless, all three compounds require monthly moni-
toring of liver function tests. ERAs are potent teratogens 
and contraception is required for women with childbearing 
potential (Spence et al 1999).
Patient-focused perspectives 
such as quality of life, patient 
satisfaction, tolerability, adherence, 
and uptake
All pivotal studies have shown improvement in functional 
capacity with ERAs compared with placebo. Only two 
studies have formerly evaluated patients’ quality of life 
using the SF-36 questionnaire; BREATHE-4 (bosentan in 
HIV) and ARIES-2 (ambrisentan), both of which showed 
signiﬁ  cant improvement. However, the SF-36 questionnaire 
which is used in patients with chronic lung disease has not 
been validated for PAH. Nevertheless, a combination of 
improvement in functional capacity, coupled with the ease 
of administration, is a major advantage of this class of thera-
pies. Since placebo control randomized studies assessing 
survival in PAH patients treated with ERAs have not been 
performed, it is difﬁ  cult to ascertain whether these drugs 
affect survival.
Conclusions, optimizing selection, 
and use in therapy
Since the discovery of  ET-1 in 1988, and its pivotal role in the 
pathogenesis of PAH, endothelin receptor antagonist thera-
pies have emerged, improving the lives of many patients with 
PAH. For patients with Group 1 PAH with a negative vasore-
activity test and NYHA class II–IV, non-selective endothelin 
receptor antagonist bosentan improves hemodynamics, 
exercise capacity and delays clinical worsening. There is 
published experience with bosentan in various subgroups of 
PAH patients. In addition, selective ETA antagonists such as 
ambrisentan and sitaxsentan also improve exercise tolerance, Vascular Health and Risk Management 2008:4(5) 951
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functional class, hemodynamics, and quality of life. To date, 
we lack comparative clinical studies to evaluate whether 
selective inhibition has a clinical advantage over nonselec-
tive inhibition. From the current data we know that the safety 
proﬁ  les and the drug-drug interactions are different for the 
different ERAs. Although monthly liver test monitoring is 
required for all three drugs, ambrisentan has the least liver 
toxicity. Concomitant warfarin therapy with sitaxsentan will 
require the warfarin dose to be reduced, while with bosentan, 
the warfarin dose must be increased, and with ambrisentan 
there is no need to alter the warfarin dose.
Many questions remain unanswered and deserve further 
study, such as understanding the pharmacogenomics of 
responders and non-responders to therapy, a better under-
standing of the importance of selectivity versus nonselectivity, 
the need for robust survival data, and determining the effec-
tive combination therapy. Limited experience suggests that 
bosentan can be used safely with epoprostenol or treprostinil. 
The beneﬁ  ts of bosentan plus sildenaﬁ  l are best described in 
patients with idiopathic PAH, and less so in scleroderma-
associated PAH. The effect of combining bosentan with 
iloprost is less clear. Larger trials are underway to investigate 
the role of combination oral therapies. Despite the ongoing 
unanswered questions, the rapid translation of basic science 
into applicable and efﬁ  cacious therapies for patients with PAH 
has had a tremendous impact in caring for these patients.
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